Reproductive factors and exogenous hormone use and risk of adult glioma in women in the NIH-AARP Diet and Health Study.
Experimental evidence suggests that estrogen and other steroid hormones may protect against glioma. Although epidemiologic studies provide only weak support for a role of exogenous or endogenous hormones in gliogenesis, few cohort studies have addressed this question. The authors, therefore, examined the association between menstrual and reproductive factors, exogenous hormone use, and glioma risk among 225,355 women aged 50-71 years who completed the baseline questionnaire in the NIH-AARP Diet and Health Study. During 7.5 years of follow-up, 174 cases of incident, primary glioma were ascertained. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for exposures, taking potential confounders into account. Older age at menarche was positively associated with risk: HR 1.67 (95% CI: 1.03, 2.69). Other reproductive factors, including age at first live birth, parity, age at menopause, type of menopause (natural vs. medical) and exogenous hormone use showed no association with glioma risk. The results were similar when the analysis was restricted to cases with glioblastoma (N = 130). The present study provides only limited support for the hypothesis that menstrual/reproductive factors or exogenous hormone use play a role in gliogenesis.
Kabat
Geoffrey C
GC
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York 10461, USA. geoffrey.kabat@einstein.yu.edu
Park
Yikyung
Y
Hollenbeck
Albert R
AR
Schatzkin
Arthur
A
Rohan
Thomas E
TE
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000209:etiology*; D015331:Cohort Studies; D004032:Diet; D005260:Female; D005910:Glioma / Q000209:etiology*; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D011446:Prospective Studies; D017584:Reproductive History; D012307:Risk Factors
Neurosurgery. 1995 Sep;37(3):496-503; discussion 503-4
7501116
J Neurooncol. 2005 Mar;72(1):11-6
15803369
Prog Neurobiol. 2001 Jan;63(1):29-60
11040417
Cancer Res. 2006 Dec 15;66(24):11991-7
17178898
J Neurosurg. 2000 Dec;93(6):932-9
11117865
Biol Reprod. 2002 Nov;67(5):1379-85
12390866
Int J Cancer. 2006 Mar 1;118(5):1321-4
16152609
Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1583-8
15466973
Cancer Causes Control. 2009 Feb;20(1):87-96
18766447
Int J Cancer. 1999 Jul 19;82(2):155-60
10389745
J Neurosurg. 1999 Jun;90(6):1072-7
10350254
J Neurooncol. 1990 Feb;8(1):55-60
2319291
Int J Cancer. 2005 May 1;114(5):797-805
15609304
Am J Epidemiol. 2001 Dec 15;154(12):1119-25
11744517
Br J Cancer. 2008 Jul 8;99(1):185-90
18560401
Cancer Causes Control. 1993 Nov;4(6):505-11
8280827
Am J Epidemiol. 2006 Oct 1;164(7):629-36
16835295
J Neurosurg. 2004 May;100(5):923-30
15137610
Cancer Lett. 2004 Sep 15;213(1):57-65
15312684
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2663-70
18843008
J Neurochem. 1994 Dec;63(6):2058-64
7964723
Nat Rev Neurosci. 2002 Jun;3(6):433-42
12042878
Neurosci Lett. 2004 Sep 30;368(3):279-84
15364411
Neuropathol Appl Neurobiol. 1990 Apr;16(2):141-51
2161085
Horm Behav. 2001 Sep;40(2):196-202
11534982
Epidemiol Rev. 1995;17(2):382-414
8654518
Clin Neuropharmacol. 1984;7(4):357-62
6509447
Int J Cancer. 1997 Jul 29;72(3):389-93
9247278